Destiny Pharma (DEST) Sets New 52-Week Low at $78.00
Shares of Destiny Pharma PLC (LON:DEST) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 78 ($1.02) and last traded at GBX 79.50 ($1.04), with a volume of 7000 shares. The stock had previously closed at GBX 80.50 ($1.05).
Separately, FinnCap reiterated a “corporate” rating on shares of Destiny Pharma in a report on Wednesday, September 26th.
About Destiny Pharma (LON:DEST)
Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections.
Recommended Story: Hedge Funds Explained
Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.